2.12
price up icon6.00%   0.12
after-market Handel nachbörslich: 2.09 -0.03 -1.42%
loading
Schlusskurs vom Vortag:
$2.00
Offen:
$2
24-Stunden-Volumen:
5.34M
Relative Volume:
1.53
Marktkapitalisierung:
$398.81M
Einnahmen:
$116.33M
Nettoeinkommen (Verlust:
$-209.25M
KGV:
-0.7518
EPS:
-2.82
Netto-Cashflow:
$-135.49M
1W Leistung:
+1.92%
1M Leistung:
-1.85%
6M Leistung:
+1.92%
1J Leistung:
+105.83%
1-Tages-Spanne:
Value
$1.965
$2.14
1-Wochen-Bereich:
Value
$1.965
$2.195
52-Wochen-Spanne:
Value
$0.865
$3.40

Esperion Therapeutics Inc Stock (ESPR) Company Profile

Name
Firmenname
Esperion Therapeutics Inc
Name
Telefon
734-887-3903
Name
Adresse
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Name
Mitarbeiter
240
Name
Twitter
@esperioninc
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
ESPR's Discussions on Twitter

Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2023-03-16 Herabstufung BofA Securities Neutral → Underperform
2023-03-16 Herabstufung Northland Capital Market Perform → Under Perform
2023-03-07 Hochstufung Credit Suisse Underperform → Neutral
2023-02-27 Fortgesetzt BofA Securities Neutral
2023-02-24 Hochstufung Jefferies Hold → Buy
2023-02-03 Hochstufung Morgan Stanley Underweight → Equal-Weight
2022-08-03 Herabstufung Credit Suisse Neutral → Underperform
2022-05-05 Hochstufung JP Morgan Underweight → Neutral
2022-03-10 Eingeleitet H.C. Wainwright Buy
2021-10-19 Herabstufung Credit Suisse Outperform → Neutral
2021-10-14 Herabstufung Morgan Stanley Equal-Weight → Underweight
2021-05-05 Herabstufung Stifel Buy → Hold
2021-04-26 Fortgesetzt Credit Suisse Outperform
2021-03-11 Eingeleitet Morgan Stanley Equal-Weight
2021-02-12 Herabstufung Jefferies Buy → Hold
2021-02-09 Herabstufung Goldman Neutral → Sell
2021-01-15 Herabstufung BofA Securities Buy → Neutral
2020-11-10 Hochstufung Credit Suisse Neutral → Outperform
2020-09-29 Fortgesetzt JP Morgan Underweight
2020-08-11 Herabstufung Credit Suisse Outperform → Neutral
2020-04-01 Fortgesetzt BofA/Merrill Buy
2020-03-17 Hochstufung Citigroup Neutral → Buy
2020-02-24 Herabstufung Northland Capital Outperform → Market Perform
2020-02-14 Herabstufung Citigroup Buy → Neutral
2019-09-16 Hochstufung Goldman Sell → Neutral
2019-05-29 Herabstufung Goldman Neutral → Sell
2019-05-06 Hochstufung BofA/Merrill Underperform → Neutral
2019-04-26 Hochstufung Goldman Sell → Neutral
2019-03-13 Hochstufung JP Morgan Underweight → Neutral
2019-01-07 Bestätigt Needham Strong Buy
2018-12-13 Eingeleitet Goldman Sell
2018-10-29 Hochstufung Northland Capital Market Perform → Outperform
2018-10-16 Eingeleitet BTIG Research Buy
2018-08-17 Hochstufung Citigroup Neutral → Buy
2018-07-11 Herabstufung Northland Capital Outperform → Market Perform
2018-05-03 Herabstufung JP Morgan Neutral → Underweight
2018-05-02 Herabstufung BofA/Merrill Buy → Underperform
Alle ansehen

Esperion Therapeutics Inc Aktie (ESPR) Neueste Nachrichten

pulisher
02:54 AM

Vanguard Group Inc's Strategic Acquisition in Esperion Therapeutics Inc - GuruFocus.com

02:54 AM
pulisher
Nov 04, 2024

Esperion to Participate in Upcoming Jefferies London Healthcare Conference - GlobeNewswire

Nov 04, 2024
pulisher
Oct 31, 2024

Esperion Announces a Featured Presentation in the Late - GlobeNewswire

Oct 31, 2024
pulisher
Oct 31, 2024

Esperion Therapeutics (ESPR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance

Oct 31, 2024
pulisher
Oct 31, 2024

Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three - The Bakersfield Californian

Oct 31, 2024
pulisher
Oct 31, 2024

Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three Poster Presentations Accepted for the 2024 American Heart Association (AHA) Scientific Sessions - Yahoo Finance

Oct 31, 2024
pulisher
Oct 31, 2024

Esperion Therapeutics (ESPR) Set to Announce Quarterly Earnings on Thursday - MarketBeat

Oct 31, 2024
pulisher
Oct 26, 2024

StockNews.com Upgrades Esperion Therapeutics (NASDAQ:ESPR) to Buy - MarketBeat

Oct 26, 2024
pulisher
Oct 24, 2024

Esperion to Report Third Quarter 2024 Financial Results on November 7 - GlobeNewswire

Oct 24, 2024
pulisher
Oct 24, 2024

ESPREsperion Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Oct 24, 2024
pulisher
Oct 23, 2024

Nexletol From Esperion - Pharmacy Times

Oct 23, 2024
pulisher
Oct 18, 2024

Esperion Therapeutics' chief commercial officer sells shares worth $226 - Investing.com

Oct 18, 2024
pulisher
Oct 18, 2024

Esperion Therapeutics' chief commercial officer sells shares worth $226 By Investing.com - Investing.com UK

Oct 18, 2024
pulisher
Oct 17, 2024

Millennium Management LLC's Strategic Reduction in Esperion Therapeutics Inc Holdings - Yahoo Finance

Oct 17, 2024
pulisher
Oct 11, 2024

Q1 2025 EPS Estimates for Esperion Therapeutics, Inc. (NASDAQ:ESPR) Reduced by Zacks Research - MarketBeat

Oct 11, 2024
pulisher
Oct 10, 2024

Zacks Research Weighs in on Esperion Therapeutics, Inc.'s FY2025 Earnings (NASDAQ:ESPR) - MarketBeat

Oct 10, 2024
pulisher
Oct 05, 2024

Esperion Therapeutics (NASDAQ:ESPR) Stock Rating Upgraded by StockNews.com - MarketBeat

Oct 05, 2024
pulisher
Oct 04, 2024

Q1 2025 EPS Estimates for Esperion Therapeutics, Inc. (NASDAQ:ESPR) Cut by Analyst - MarketBeat

Oct 04, 2024
pulisher
Oct 03, 2024

Esperion shares reiterate Buy rating on trial data By Investing.com - Investing.com South Africa

Oct 03, 2024
pulisher
Oct 03, 2024

Esperion shares reiterate Buy rating on trial data - Investing.com India

Oct 03, 2024
pulisher
Oct 03, 2024

Is Esperion Therapeutics, Inc. (ESPR) the Best NASDAQ Stock Under $5? - Insider Monkey

Oct 03, 2024
pulisher
Oct 02, 2024

Esperion reports LDL-C reduction success in MILOS study By Investing.com - Investing.com South Africa

Oct 02, 2024
pulisher
Oct 02, 2024

Esperion reports LDL-C reduction success in MILOS study - Investing.com

Oct 02, 2024
pulisher
Oct 02, 2024

Esperion Therapeutics' (ESPR) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat

Oct 02, 2024
pulisher
Oct 02, 2024

Esperion EU Partner Reports Final Real-World Results from MILOS German Cohort Demonstrating Strong Increase in LDL-C Goal Achievement With Addition of Bempedoic Acid - The Manila Times

Oct 02, 2024
pulisher
Oct 02, 2024

Esperion EU Partner Reports Final Real-World Results from - GlobeNewswire

Oct 02, 2024
pulisher
Sep 30, 2024

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Sees Large Decline in Short Interest - MarketBeat

Sep 30, 2024
pulisher
Sep 30, 2024

Marshall Wace LLP Raises Stock Holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - MarketBeat

Sep 30, 2024
pulisher
Sep 30, 2024

7 Best NASDAQ Stocks Under $5 - Insider Monkey

Sep 30, 2024
pulisher
Sep 27, 2024

Esperion Therapeutics (NASDAQ:ESPR) Lowered to Hold at StockNews.com - MarketBeat

Sep 27, 2024
pulisher
Sep 25, 2024

Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire

Sep 25, 2024
pulisher
Sep 25, 2024

Edesa Biotech (NASDAQ:EDSA) Shares Down 1.6% - Defense World

Sep 25, 2024
pulisher
Sep 24, 2024

Taking a Closer Look At Esperion Therapeutics Inc. (ESPR) Following Its Recent Trade - Knox Daily

Sep 24, 2024
pulisher
Sep 24, 2024

ESH Acquisition Corp. (NASDAQ:ESHA) Shares Bought by Berkley W R Corp - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

What's Going On With Seelos Therapeutics Stock Tuesday? - Benzinga

Sep 24, 2024
pulisher
Sep 24, 2024

Great Point Partners LLC Sells 2,208,406 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

ESAB Co. (NYSE:ESAB) Stock Position Cut by Front Street Capital Management Inc. - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

Seelos Therapeutics surges on deal with U.S. Army to develop PTSD drug - XM

Sep 24, 2024
pulisher
Sep 24, 2024

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Shares Sold by Great Point Partners LLC - MarketBeat

Sep 24, 2024
pulisher
Sep 24, 2024

New Pill Cuts Cholesterol and Heart Attacks - Greek Reporter

Sep 24, 2024
pulisher
Sep 23, 2024

What to expect from Esperion Therapeutics Inc.’s (ESPR) current quarter earnings? - US Post News

Sep 23, 2024
pulisher
Sep 23, 2024

Atopic dermatitis: New drug significantly improves symptoms - Medical News Today

Sep 23, 2024
pulisher
Sep 23, 2024

How does ESAB Corp (ESAB) change from a tortoise to a hare? - SETE News

Sep 23, 2024
pulisher
Sep 23, 2024

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Stake Raised by XTX Topco Ltd - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

XTX Topco Ltd Has $810,000 Stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - MarketBeat

Sep 23, 2024
pulisher
Sep 23, 2024

Espey Mfg. & Electronics (NYSEAMERICAN:ESP) Receives New Coverage from Analysts at StockNews.com - Defense World

Sep 23, 2024
pulisher
Sep 21, 2024

Inspire Investing LLC Invests $758,000 in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - MarketBeat

Sep 21, 2024
pulisher
Sep 20, 2024

ESAB Co. (NYSE:ESAB) Shares Sold by Granite Investment Partners LLC - Defense World

Sep 20, 2024
pulisher
Sep 20, 2024

Bank of New York Mellon Corp Acquires 555,382 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) - MarketBeat

Sep 20, 2024
pulisher
Sep 19, 2024

18,727 Shares in ESAB Co. (NYSE:ESAB) Bought by Seven Eight Capital LP - Defense World

Sep 19, 2024

Finanzdaten der Esperion Therapeutics Inc-Aktie (ESPR)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$12.67
price up icon 0.88%
$114.96
price down icon 0.42%
$89.24
price up icon 3.56%
$58.48
price down icon 0.36%
$121.53
price up icon 0.83%
$11.61
price up icon 1.40%
Kapitalisierung:     |  Volumen (24h):